Evidence map›Paper›PMID 35616938›Full record

Observational studyJAMA network open2022

SARS-CoV-2 Attack Rate and Population Immunity in Southern New England, March 2020 to May 2021.

Thu Nguyen-Anh Tran, Nathan B Wikle, Fuhan Yang, Haider Inam, Scott Leighow, Bethany Gentilesco, Philip Chan, Emmy Albert, Emily R Strong, Justin R Pritchard and 4 more

Abstract readObservational Study
In one paragraph

Observational study in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Thu Nguyen-Anh TranCenter for Infectious Disease Dynamics, Department of Biology, Pennsylvania State University, University Park.
Nathan B WikleCenter for Infectious Disease Dynamics, Department of Statistics, Pennsylvania State University, University Park.
Fuhan YangCenter for Infectious Disease Dynamics, Department of Biology, Pennsylvania State University, University Park.
Haider InamCenter for Infectious Disease Dynamics, Department of Bioengineering, Pennsylvania State University, University Park.
Scott LeighowCenter for Infectious Disease Dynamics, Department of Bioengineering, Pennsylvania State University, University Park.
Bethany GentilescoDepartment of Medicine, Brown University, Providence, Rhode Island.
Philip ChanDepartment of Medicine, Brown University, Providence, Rhode Island.
Emmy AlbertDepartment of Physics, Pennsylvania State University, University Park.
Emily R StrongCenter for Infectious Disease Dynamics, Department of Statistics, Pennsylvania State University, University Park.
Justin R PritchardCenter for Infectious Disease Dynamics, Department of Bioengineering, Pennsylvania State University, University Park.
William P HanageCenter for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Ephraim M HanksCenter for Infectious Disease Dynamics, Department of Statistics, Pennsylvania State University, University Park.
Forrest W CrawfordDepartment of Biostatistics, Yale School of Public Health, New Haven, Connecticut.
Maciej F BoniCenter for Infectious Disease Dynamics, Department of Biology, Pennsylvania State University, University Park.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: In emergency epidemic and pandemic settings, public health agencies need to be able to measure the population-level attack rate, defined as the total percentage of the population infected thus far. During vaccination campaigns in such settings, public health agencies need to be able to assess how much the vaccination campaign is contributing to population immunity; specifically, the proportion of vaccines being administered to individuals who are already seropositive must be estimated. Objective: To estimate population-level immunity to SARS-CoV-2 through May 31, 2021, in Rhode Island, Massachusetts, and Connecticut. Design, Setting, and Participants: This observational case series assessed cases, hospitalizations, intensive care unit occupancy, ventilator occupancy, and deaths from March 1, 2020, to May 31, 2021, in Rhode Island, Massachusetts, and Connecticut. Data were analyzed from July 2021 to November 2021. Exposures: COVID-19-positive test result reported to state department of health. Main Outcomes and Measures: The main outcomes were statistical estimates, from a bayesian inference framework, of the percentage of individuals as of May 31, 2021, who were (1) previously infected and vaccinated, (2) previously uninfected and vaccinated, and (3) previously infected but not vaccinated. Results: At the state level, there were a total of 1 160 435 confirmed COVID-19 cases in Rhode Island, Massachusetts, and Connecticut. The median age among individuals with confirmed COVID-19 was 38 years. In autumn 2020, SARS-CoV-2 population immunity (equal to the attack rate at that point) in these states was less than 15%, setting the stage for a large epidemic wave during winter 2020 to 2021. Population immunity estimates for May 31, 2021, were 73.4% (95% credible interval [CrI], 72.9%-74.1%) for Rhode Island, 64.1% (95% CrI, 64.0%-64.4%) for Connecticut, and 66.3% (95% CrI, 65.9%-66.9%) for Massachusetts, indicating that more than 33% of residents in these states were fully susceptible to infection when the Delta variant began spreading in July 2021. Despite high vaccine coverage in these states, population immunity in summer 2021 was lower than planned owing to an estimated 34.1% (95% CrI, 32.9%-35.2%) of vaccines in Rhode Island, 24.6% (95% CrI, 24.3%-25.1%) of vaccines in Connecticut, and 27.6% (95% CrI, 26.8%-28.6%) of vaccines in Massachusetts being distributed to individuals who were already seropositive. Conclusions and Relevance: These findings suggest that future emergency-setting vaccination planning may have to prioritize high vaccine coverage over optimized vaccine distribution to ensure that sufficient levels of population immunity are reached during the course of an ongoing epidemic or pandemic.

Indexed as

COVID-19SARS-CoV-2AdultBayes TheoremCOVID-19 VaccinesHumansIncidenceNew EnglandCOVID-19 Vaccines

Identifiers

PMID35616938
PMCPMC9136627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.